M&A Deal Summary

Boehringer Ingelheim Acquires NBE-Therapeutics AG

On December 10, 2020, Boehringer Ingelheim acquired life science company NBE-Therapeutics AG from PPF Group for 1.2B EUR

Acquisition Highlights
  • This is Boehringer Ingelheim’s 7th transaction in the Life Science sector.
  • This is Boehringer Ingelheim’s 0th largest (disclosed) transaction.
  • This is Boehringer Ingelheim’s 2nd transaction in Switzerland.

M&A Deal Summary
Date 2020-12-10
Target NBE-Therapeutics AG
Sector Life Science
Buyer(s) Boehringer Ingelheim
Sellers(s) PPF Group
Deal Type Add-on Acquisition
Deal Value 1.2B EUR

Target

NBE-Therapeutics AG

Basel, Switzerland
NBE-Therapeutics is a privately-owned Swiss biotech company based in Basel and founded in 2012 with the vision of developing next-generation immune-stimulatory antibody-drug conjugate (iADC) products. NBE-Therapeutics advances its products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb Display technology for antibody discovery, its SMAC-Technology for site-specific payload conjugation of toxins to antibodies, and a novel highly effective and immune-stimulatory anthracycline-based toxin platform.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Boehringer Ingelheim

Ingelheim am Rhein, Germany
Category Company
Sector Healthcare Services
DESCRIPTION

Boehringer Ingelheim is a global group of companies embracing many cultures and diverse societies.

DEAL STATS #
Overall 9 of 13
Sector (Life Science) 7 of 11
Type (Add-on Acquisition) 8 of 11
Country (Switzerland) 2 of 3
Year (2020) 5 of 5
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-09 Labor Dr. Merk & Kollegen

Ochsenhausen, Germany

Labor Dr. Merk & Kollegen GmbH is in a process development, manufacturing and analytical characterization of viral therapeutics and oncolytic viral therapeutics. Labor Dr. Merk & Kollegen is based in Ochsenhausen, Germany.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-09-21 Abexxa Biologics

Arlington, Texas, United States

Abexxa Biologics is a biopharmaceutical company taking an approach in the fields of immuno-oncology and oncology to develop the next generation of precision medicine. Abexxa is focused on developing novel therapeutics around its newly discovered class of intracellular antigens (atypical HLA-peptide complexes) on cancerous cells. Abexxa Biologics is based in Arlington, Texas.

Buy -

Seller(S) 1

SELLER

PPF Group

Investor Investor Investor

Category Family Office
Founded 1991
PE ASSETS 40.0B EUR
Size Mega
Type Sector Agnostic
DESCRIPTION

DEAL STATS #
Overall 3 of 3
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (Switzerland) 1 of 1
Year (2020) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-05-22 Temsa

Adana, Turkey

Temsa develops and makes a wide range of transportation products, including municipal and intercity buses, tourist coaches, commercial vehicles, and propulsion systems including modern electric units. Temsa was formed in 1968 and is based in Adana, Turkey.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-06-10 FAST

Prague, Czech Republic

FAST is a retail and distribution company wholesaling and retailing brand-name consumer electronics, tools, telecommunications and office equipment. FAST was founded in 1992 and is based in Prague, Czech Republic.

Buy -
Mergr

Product

Company

Legal